Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Gemtuzumab Ozogamicin in Favorable and Intermediate Risk Acute Myeloid Leukemia: A Single-Center Experience

Jia Li Liu, Nushin Sadeghi, Owen Luo, Jonathan How, John M. Storring, Gizelle Popradi

Blood (2024) 144 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2024-198536

Published: 2024

Journal Articles

Open-Label Phase 1 Study to Evaluate the Safety of SGN-35T in Patients with Relapsed/Refractory CD30-Expressing Lymphoid Malignancies (SGN35T-001; trial in progress)

Tatyana Feldman, Hun Ju Lee, Gizelle Popradi, Graham P. Collins, Daniel Morillo, Ming Jin Yan, Tara Chen, Youn H. Kim

Blood (2024) 144 (Supplement 1): 6356.

https://doi.org/10.1182/blood-2024-200265

Published: 2024

Journal Articles

Age ≥60 Is an Added Risk Factor for Mortality in High-Risk HCT-CI Patients Undergoing Allogeneic Stem Cell Transplant

Veronica Ramirez, Gizelle Popradi, John M. Storring, Jonathan How

Blood (2024) 144 (Supplement 1): 7926.

https://doi.org/10.1182/blood-2024-204066

Published: 2024

Journal Articles

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Blood (2024) 144 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2024-204004

Published: 2024

Journal Articles

Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study

Marcos J.G. de Lima, Partow Kebriaei, Francesco Lanza, Christina Cho, Gizelle Popradi, Michael T Hemmer, Mei-Jie Zhang, Fan Zhang, Richa Shah, Verna Welch, Saara Tikka, Erik Vandendries, Matthias Stelljes, David I. Marks, Wael Saber

Blood (2022) 140 (Supplement 1): 6023–6025.

https://doi.org/10.1182/blood-2022-160315

Published: 2022

Journal Articles

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Jean Roy, MD, Tony Panzarella, M.Sc., P.Stat, Stephen Couban, MDBSc, Félix Couture, MD FRCPC, Gerald M. Devins, PhD, Mohamed Elemary, MD, Stephen Ronan Foley, MD FRCPC, Genevieve Gallagher, MD, John Kuruvilla, MD, Stephanie J. Lee, MD MPH, John Moore, MDFRACP,FRCPA, Thomas J Nevill, MD, Gizelle Popradi, MD FRCP, Kirk R. Schultz, MD, David Szwajcer, MD FRCPC, Cynthia L Toze, MD FRCPC, Irwin Walker, MBBS, FRCPC

Blood (2019) 134 (Supplement_1): 875.

https://doi.org/10.1182/blood-2019-123275

Published: 2019

Journal Articles

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3 + NK cells

Blood (2016) 127 (24): 3082–3091.

https://doi.org/10.1182/blood-2015-09-668251

Published: 2016

Includes: Supplemental data

Journal Articles

Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial

Irwin Walker, MBBS, Kirk R. Schultz, MD, Cynthia L. Toze, MD FRCPC, Holly Margaret Kerr, RN, BSN, John Moore, MD, David Szwajcer, MD FRCPC, Stephen Ronan Foley, MD FRCPC, John Kuruvilla, MD FRCPC, Tony Panzarella, M.Sc, Félix Couture, MD, Jean Roy, MD, Stephen Couban, MD FRCPC, Gerald Devins, PhD, Gizelle Popradi, FRCPC, MD, Stephanie J. Lee, MD MPH, Jason Tay, MD MSc, FRCPC, Thomas J. Nevill, MD FRCPC, Mohamed Elemary, MD MSc,PhD, Genevieve Gallagher, MD FRCPC

Blood (2014) 124 (21): 38.

https://doi.org/10.1182/blood.V124.21.38.38

Published: 2014

Journal Articles

Impact of Myeloablative Versus Reduced Intensity Conditioning Regimens on Early Lymphocyte Recovery and Its Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients with Hematologic Malignancies.

Dong Hwan (Dennis) Kim, MD, PhD, Gizelle Popradi, MD, John Kuruvilla, MD, Vikas Gupta, MD, Mark Minden, MD, PhD, Jeffrey H. Lipton, MD, PhD, Hans A. Messner, MD, PhD

Blood (2007) 110 (11): 5039.

https://doi.org/10.1182/blood.V110.11.5039.5039

Published: 2007

Journal Articles

Late Onset Eosinophilia (beyond Day 100), Rather Than Early Onset Eosinophilia, Has a Significant Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).

Dong Hwan (Dennis) Kim, MD, PhD, Gizelle Popradi, MD, John Kuruvilla, MD, Vikas Gupta, MD, Mark Minden, MD, PhD, Hans A. Messner, MD, PhD, Jeffrey H. Lipton, MD, PhD

Blood (2007) 110 (11): 1062.

https://doi.org/10.1182/blood.V110.11.1062.1062

Published: 2007

Journal Articles

Early Recovery of Absolute Lymphocyte Count (ALC) Is a Predictor of Long-Term Outcome Following Related Allogeneic Peripheral Blood Stem Cell Transplantation in Adults with AML/MDS.

Gizelle Popradi, MD, Dong Hwan (Dennis) Kim, MD/PhD, John Kuruvilla, MD, Vikas Gupta, MD, Mark Minden, MD/PhD, Jeffrey H. Lipton, MD/PhD, Hans A. Messner, MD/PhD

Blood (2007) 110 (11): 1102.

https://doi.org/10.1182/blood.V110.11.1102.1102

Published: 2007

NARROW

Gemtuzumab Ozogamicin in Favorable and Intermediate Risk Acute Myeloid Leukemia: A Single-Center Experience

Open-Label Phase 1 Study to Evaluate the Safety of SGN-35T in Patients with Relapsed/Refractory CD30-Expressing Lymphoid Malignancies (SGN35T-001; trial in progress)

Age ≥60 Is an Added Risk Factor for Mortality in High-Risk HCT-CI Patients Undergoing Allogeneic Stem Cell Transplant

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3 + NK cells

Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial

Impact of Myeloablative Versus Reduced Intensity Conditioning Regimens on Early Lymphocyte Recovery and Its Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients with Hematologic Malignancies.

Late Onset Eosinophilia (beyond Day 100), Rather Than Early Onset Eosinophilia, Has a Significant Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).

Early Recovery of Absolute Lymphocyte Count (ALC) Is a Predictor of Long-Term Outcome Following Related Allogeneic Peripheral Blood Stem Cell Transplantation in Adults with AML/MDS.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only